Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Desmopressin is used in children with nocturnal enuresis, and it has recently shown some promise in the treatment of OAB in adults. Desmopressin is a synthetic analogue of vasopressin and thus ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Overactive bladder is a specific type of voiding dysfunction that includes any or all of the following symptoms: urinary frequency (bothersome urination eight or more times a day or two more times ...

Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase I for Overactive Bladder.